Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
Xgeva (denosumab) is an antibody that binds to RANKL protein, inhibiting osteoclast activity and is FDA approved for use in patients with giant cell tumor of the bone (FDA.gov).
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Denosumab||Xgeva||AMG162|AMG-162|AMG 162|Prolia||Xgeva (denosumab) is an antibody that binds to RANKL protein, inhibiting osteoclast activity and is FDA approved for use in patients with giant cell tumor of the bone (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT02833610||Phase II||Denosumab||A Study of Denosumab in Multiple Myeloma Patients With Renal Insufficiency||Unknown status||USA||0|
|NCT02470091||Phase II||Denosumab||Denosumab in Treating Patients With Recurrent or Refractory Osteosarcoma||Active, not recruiting||USA | CAN||1|
|NCT03301857||Phase III||Denosumab||Long-term Safety Follow-up of Subjects With Giant Cell Tumor of Bone Treated With Denosumab in Study 20062004||Active, not recruiting||USA | ITA | FRA | ESP||4|
|NCT02900469||Phase 0||Denosumab||Safety Study of Denosumab to Treat Breast Cancer||Completed||USA||0|
|NCT03839459||Phase II||Denosumab||Denosumab for Smoldering Multiple Myeloma||Active, not recruiting||USA||0|
|NCT03605199||Phase II||Denosumab||Denosumab in Subjects With Giant Cell Rich Tumors of Bone||Recruiting||ITA | FRA||1|
|NCT01545648||Phase II||Denosumab||Pilot Study to Evaluate the Impact of Denosumab on Disseminated Tumor Cells (DTC) in Patients With Early Stage Breast Cancer||Terminated||USA||0|
|NCT01345019||Phase III||Denosumab Zoledronic acid||Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma||Completed||USA | ITA | FRA | ESP | DEU | CAN | AUT||22|
|NCT00680992||Phase II||Denosumab||Study of Denosumab in Subjects With Giant Cell Tumor of Bone||Completed||USA | ITA | FRA | ESP | DEU | CAN | AUT||5|
|NCT03070002||Phase II||Denosumab||Denosumab in Treating Patients With ER and/or PR Positive, HER2 Negative Metastatic Breast Cancer With Bone Metastases and Detectable Circulating Tumor Cells||Terminated||USA||0|
|NCT01952054||Phase II||Denosumab||Denosumab for Breast Cancer With Bone Mets||Terminated||USA||0|